Financhill
Buy
60

CKPT Quote, Financials, Valuation and Earnings

Last price:
$4.28
Seasonality move :
-6.76%
Day range:
$4.23 - $4.28
52-week range:
$1.80 - $4.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
22.75x
Volume:
8.7M
Avg. volume:
1.8M
1-year change:
132.79%
Market cap:
$370.7M
Revenue:
$41K
EPS (TTM):
-$1.29

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CKPT
Checkpoint Therapeutics
-- -$0.10 17663.42% -88.89% $4.33
AKYA
Akoya Biosciences
$19.3M -$0.23 -21.86% -14.82% $1.88
FBIO
Fortress Biotech
$11.6M -$0.44 -2.43% -57.53% $10.00
QTRX
Quanterix
$28.3M -$0.69 -10.47% -- $11.25
RIGL
Rigel Pharmaceuticals
$43.9M $0.09 86.28% 1057.82% $33.74
TRVI
Trevi Therapeutics
-- -$0.12 -- -15.28% $20.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CKPT
Checkpoint Therapeutics
$4.26 $4.33 $370.7M -- $0.00 0% --
AKYA
Akoya Biosciences
$1.24 $1.88 $61.8M -- $0.00 0% 0.77x
FBIO
Fortress Biotech
$1.95 $10.00 $57.7M -- $0.00 0% 0.76x
QTRX
Quanterix
$5.28 $11.25 $205M -- $0.00 0% 1.52x
RIGL
Rigel Pharmaceuticals
$19.19 $33.74 $343M 9.27x $0.00 0% 1.68x
TRVI
Trevi Therapeutics
$6.26 $20.67 $636.9M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CKPT
Checkpoint Therapeutics
-- -0.009 -- 0.23x
AKYA
Akoya Biosciences
108.34% 0.070 110.41% 0.36x
FBIO
Fortress Biotech
72.36% 0.006 103.39% 1.49x
QTRX
Quanterix
-- 0.645 -- 7.31x
RIGL
Rigel Pharmaceuticals
76.29% 6.907 18.59% 1.78x
TRVI
Trevi Therapeutics
-- -3.778 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CKPT
Checkpoint Therapeutics
-- -$9.6M -- -- -16275.61% -$11.7M
AKYA
Akoya Biosciences
$9.9M -$13.3M -52.81% -338.02% -78.8% -$7.4M
FBIO
Fortress Biotech
$8.3M -$22.3M -67.58% -- -168.82% -$19.6M
QTRX
Quanterix
$16.4M -$26.4M -14.39% -14.39% -87.09% -$15.1M
RIGL
Rigel Pharmaceuticals
$48.9M $12.8M 76.12% -- 25.06% -$893K
TRVI
Trevi Therapeutics
-- -$11.5M -- -- -- -$13.5M

Checkpoint Therapeutics vs. Competitors

  • Which has Higher Returns CKPT or AKYA?

    Akoya Biosciences has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -94.07%. Checkpoint Therapeutics's return on equity of -- beat Akoya Biosciences's return on equity of -338.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.19 -$15.7M
    AKYA
    Akoya Biosciences
    59.33% -$0.32 $70.6M
  • What do Analysts Say About CKPT or AKYA?

    Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 1.72%. On the other hand Akoya Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 51.82%. Given that Akoya Biosciences has higher upside potential than Checkpoint Therapeutics, analysts believe Akoya Biosciences is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    1 2 0
    AKYA
    Akoya Biosciences
    0 7 0
  • Is CKPT or AKYA More Risky?

    Checkpoint Therapeutics has a beta of 1.179, which suggesting that the stock is 17.928% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CKPT or AKYA?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or AKYA?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Akoya Biosciences quarterly revenues of $16.6M. Checkpoint Therapeutics's net income of -$11.2M is higher than Akoya Biosciences's net income of -$15.7M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.77x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$11.2M
    AKYA
    Akoya Biosciences
    0.77x -- $16.6M -$15.7M
  • Which has Higher Returns CKPT or FBIO?

    Fortress Biotech has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -80.55%. Checkpoint Therapeutics's return on equity of -- beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.19 -$15.7M
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
  • What do Analysts Say About CKPT or FBIO?

    Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 1.72%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 412.82%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    1 2 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is CKPT or FBIO More Risky?

    Checkpoint Therapeutics has a beta of 1.179, which suggesting that the stock is 17.928% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

  • Which is a Better Dividend Stock CKPT or FBIO?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or FBIO?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Checkpoint Therapeutics's net income of -$11.2M is lower than Fortress Biotech's net income of -$10.6M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.76x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$11.2M
    FBIO
    Fortress Biotech
    0.76x -- $13.1M -$10.6M
  • Which has Higher Returns CKPT or QTRX?

    Quanterix has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -67.73%. Checkpoint Therapeutics's return on equity of -- beat Quanterix's return on equity of -14.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.19 -$15.7M
    QTRX
    Quanterix
    54.03% -$0.53 $316.4M
  • What do Analysts Say About CKPT or QTRX?

    Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 1.72%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 113.07%. Given that Quanterix has higher upside potential than Checkpoint Therapeutics, analysts believe Quanterix is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    1 2 0
    QTRX
    Quanterix
    1 2 0
  • Is CKPT or QTRX More Risky?

    Checkpoint Therapeutics has a beta of 1.179, which suggesting that the stock is 17.928% more volatile than S&P 500. In comparison Quanterix has a beta of 1.116, suggesting its more volatile than the S&P 500 by 11.641%.

  • Which is a Better Dividend Stock CKPT or QTRX?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or QTRX?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Quanterix quarterly revenues of $30.3M. Checkpoint Therapeutics's net income of -$11.2M is higher than Quanterix's net income of -$20.5M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.52x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$11.2M
    QTRX
    Quanterix
    1.52x -- $30.3M -$20.5M
  • Which has Higher Returns CKPT or RIGL?

    Rigel Pharmaceuticals has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of 21.46%. Checkpoint Therapeutics's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.19 -$15.7M
    RIGL
    Rigel Pharmaceuticals
    91.73% $0.63 $78.3M
  • What do Analysts Say About CKPT or RIGL?

    Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 1.72%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 75.83%. Given that Rigel Pharmaceuticals has higher upside potential than Checkpoint Therapeutics, analysts believe Rigel Pharmaceuticals is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    1 2 0
    RIGL
    Rigel Pharmaceuticals
    1 4 0
  • Is CKPT or RIGL More Risky?

    Checkpoint Therapeutics has a beta of 1.179, which suggesting that the stock is 17.928% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.678%.

  • Which is a Better Dividend Stock CKPT or RIGL?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or RIGL?

    Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Checkpoint Therapeutics's net income of -$11.2M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.68x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$11.2M
    RIGL
    Rigel Pharmaceuticals
    1.68x 9.27x $53.3M $11.4M
  • Which has Higher Returns CKPT or TRVI?

    Trevi Therapeutics has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of --. Checkpoint Therapeutics's return on equity of -- beat Trevi Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CKPT
    Checkpoint Therapeutics
    -- -$0.19 -$15.7M
    TRVI
    Trevi Therapeutics
    -- -$0.09 --
  • What do Analysts Say About CKPT or TRVI?

    Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 1.72%. On the other hand Trevi Therapeutics has an analysts' consensus of $20.67 which suggests that it could grow by 230.14%. Given that Trevi Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Trevi Therapeutics is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CKPT
    Checkpoint Therapeutics
    1 2 0
    TRVI
    Trevi Therapeutics
    7 0 0
  • Is CKPT or TRVI More Risky?

    Checkpoint Therapeutics has a beta of 1.179, which suggesting that the stock is 17.928% more volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.428%.

  • Which is a Better Dividend Stock CKPT or TRVI?

    Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CKPT or TRVI?

    Checkpoint Therapeutics quarterly revenues are $41K, which are larger than Trevi Therapeutics quarterly revenues of --. Checkpoint Therapeutics's net income of -$11.2M is lower than Trevi Therapeutics's net income of -$10.3M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$11.2M
    TRVI
    Trevi Therapeutics
    -- -- -- -$10.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 34.96% over the past day.

Buy
87
ELF alert for May 30

e.l.f. Beauty [ELF] is up 23.68% over the past day.

Buy
67
BBW alert for May 30

Build-A-Bear Workshop [BBW] is up 21.83% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock